[go: up one dir, main page]

WO2017080989A1 - (r)-fluriprofène pour la prévention et/ou le traitement du diabète - Google Patents

(r)-fluriprofène pour la prévention et/ou le traitement du diabète Download PDF

Info

Publication number
WO2017080989A1
WO2017080989A1 PCT/EP2016/076954 EP2016076954W WO2017080989A1 WO 2017080989 A1 WO2017080989 A1 WO 2017080989A1 EP 2016076954 W EP2016076954 W EP 2016076954W WO 2017080989 A1 WO2017080989 A1 WO 2017080989A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
diabetes
flurbiprofen
coo
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/076954
Other languages
English (en)
Inventor
Gerd Geisslinger
Michael Parnham
Marc BERNAU
Rolf Michael NÜSING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Original Assignee
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV filed Critical Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Publication of WO2017080989A1 publication Critical patent/WO2017080989A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a compound being an (R)-enantiomer of a compound according to the following formula
  • Rl or R2 is a group selected from H, -CH3, -CH2CH3, -CH2CH2CH3, and CH2CH2CH2CH3 or can be taken together with another to give a cyclopropyl ring, a cyclobutyl ring, a cyclopentyl ring, or a cyclohexyl ring
  • R3 is a group selected from -COOH, -COOR6, -CONH2, -CONHR6, -CONR6R7, -CONHS02R6, -COO-(CH2)3-CH20H, -COO- (CH2)4-ON02, -COO-PhOCH3-C2H2-COO-(CH2)4-ON02, tetrazolyl, and a -COOH bioisostere
  • R4 or R5 is a group selected from -CI, -F, -Br, -I, -CF3, -OCF3, -S
  • Diabetes mellitus also referred to as diabetes, is a disease of a perturbed metabolism resulting in abnormally high blood sugar levels. Patients with diabetes do not sufficiently produce or respond to the endogenous hormone insulin that is normally produced by the beta cells of the pancreas and is important for controlling glucose levels in the blood. Typical symptoms of diabetes include frequent urination, increased thirst, weight loss, fatigue and blurry vision (Cooke et al. (2008); Type 1 diabetes mellitus in pediatrics. Pediatr Rev 29 (11): 374-84.).
  • diabetes can be subdivided into four categories:
  • Type 1 diabetes is considered to be an autoimmune disease and develops due to an absent or reduced production of insulin. Insulin production is low or even absent because the body's immune system attacks the insulin-producing beta cells of the islets of Langerhans in the pancreas. The progressive destruction of beta cells can last months or even years without clinical symptoms until a point is reached where the beta-cell mass is critically low, so that insulin concentrations are no longer adequate to control plasma glucose levels.
  • the type 1 diabetes is sometimes also referred to as "juvenile diabetes” because it mainly develops during childhood; however, it can also develop in adults. Type 1 diabetes is thought to be partly inherited and triggered by environmental factors, i.e. a viral infection, in genetically susceptible people. People with an increased risk of developing type I diabetes often have mutations in multiple genes. Most commonly, those mutations affect the group of human leukocyte antigen (HLA) genes which encode for proteins on the surface of cells that are responsible for regulation of the human immune system.
  • HLA human leukocyte antigen
  • Type 2 diabetes develops due to a resistance to the effects of insulin.
  • Type 2 diabetes is the most common form of diabetes and is primarily related to lifestyle factors such as obesity, poor diet and lack of physical activity.
  • genetic predispositions may also play an important role in the onset of type 2 diabetes, i.e. mutations in the insulin receptor gene (ISNR) decreasing insulin receptor signaling.
  • the insulin receptor is a transmembrane receptor that is activated by the hormone insulin and regulates glucose uptake into the cells. Impaired uptake of glucose into the cells, i.e. by decreased insulin receptor signaling, causes an increase of circulating glucose in the blood (hyperglycemia).
  • Type 3 diabetes comprises all other specific types of diabetes characterized by an impaired glucose metabolism resulting in hyperglycaemia.
  • the beta cells may have genetic defects affecting insulin production, insulin resistance may be caused genetically or the pancreas as such may be destroyed or impaired.
  • hormone deregulation or drugs may also cause type 3 diabetes.
  • Type 4 diabetes also known as gestational diabetes
  • Gestational diabetes is thought to be linked to pregnancy-related factors such as the presence of human placental lactogen. These factors are likely to interfere with insulin receptor signalling, thus lowering the uptake of glucose into the cells causing elevated blood sugar levels.
  • pre-diabetic states are known in the art in which not all of the symptoms required to label a person as diabetic are present, but blood sugar is abnormally high. Pre- diabetic states may include, for example, impaired fasting glycaemia, impaired glucose tolerance, obesity and metabolic syndrome.
  • Diabetes is currently based on monitoring the blood sugar levels and reducing an elevated level of blood sugar into a normal level.
  • glucose levels in the blood may be regulated by nutritional diets and the exclusion of life-style risk factors, such as smoking, lack of exercise, high cholesterol levels, and increased body weight.
  • sensitization to endogenous insulin can be achieved by administration of insulin-sensitizing drugs such as metformin and thiazolinediones.
  • administration of exogenous insulin is required.
  • Exogenous insulin is usually administered by multiple injections into the blood or by using an insulin pump. All of the current treatment options have certain limitations or drawbacks, for example insufficient response to the treatment or pain and site reactions caused by multiple injections.
  • the present invention pertains to a compound being an (R)-enantiomer of a compound according to the following formula (I)
  • Ri or R 2 is a group selected from H, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , and CH 2 CH 2 CH 2 CH 3 or can be taken together with another to give a cyclopropyl ring, a cyclobutyl ring, a cyclopentyl ring, or a cyclohexyl ring,
  • R 3 is a group selected from -COOH, -COORe, -CONH 2 , -CONHRg, -CONReRy, - CONHS0 2 R 6 , -COO-(CH 2 ) 3 -CH 2 OH, -COO-(CH 2 ) 4 -ON0 2 , -COO-PhOCH 3 -C 2 H 2 -COO- (CH 2 ) 4 -ON0 2 , tetrazolyl, and a -COOH bioisostere,
  • Rl is hydrogen (H).
  • the compound for use is selected from the group of consisting of:
  • the compound for use is (R)- Flurbiprofen (Tarenflurbil) or Nitro-(R)-Flurbiprofen.
  • (R)-Flurbiprofen the R-enantiomer of racemic Flurbiprofen, belongs to the group of 2-aryl propionic acids (profens) such as Ibuprofen and Naproxen.
  • profens 2-aryl propionic acids
  • (R)-Flurbiprofen is a by-product of the marketed racemic Flurbiprofen, the active agent of which is thought to be the (S)- enantiomer.
  • (R)-Flurbiprofen is currently in clinical trials for the treatment of metastatic prostate cancer (NCT00045123: ClinicalTrials.gov Identifier NCT00045123: R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence.
  • (R)-Flurbiprofen has been shown to modulate the enzyme gamma-secretase, which cleaves the amyloid precursor protein and is thought to be involved in the development of Alzheimer ' s disease (Geerts, 2007)). Furthermore, R-Fluriprofen has been suggested to exert an anti-inflammatory effect and has been proposed as novel therapeutic agent for the treatment of multiple sclerosis (MS) (WO 2012/059541) as well as for the treatment of skin diseases (WO 2013/026772 Al).
  • MS multiple sclerosis
  • Tarenflurbil the single enantiomer of the racemate NSAID Flurbiprofen, also designated as Flurizan, (R)-Fluriprofen or (R)-2-(2-fluoro-4-phenylphenyl)propionic acid), was investigated in phase II and phase III clinical trials for Alzheimer ' s disease. However, the further development for this indication was stopped in 2008 after an insufficient improvement of cognitive functions was found. (Green et al. (2009); Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild
  • Alzheimer disease a randomized controlled trial. JAMA. 2009;302:2557-64; Geerts (2007);
  • the compound for use according to the present invention can be provided to the patient in any suitable and effective manner, such as orally, rectally or by injection. Preferably, the compound is administered orally. Furthermore, the compound for use according to the present invention can be provided to the patient in any suitable and effective pharmaceutically acceptable form, such as in the form of a tablet, capsule, dragee, powder, suppository, gel and/or as solution for injection.
  • the compound for use according to the present invention and, preferably, R-Flurbiprofen or Nitro-R-Flurbiprofen, shall be provided to the patient in an effective dose for the prevention and/or treatment of diabetes.
  • Envisaged is a dosage in the range of about 2 mg/kg of body weight to about 20 mg/kg of body weight per day.
  • the compound is provided in a dosage between 5 mg/kg of body weight to 15 mg/kg of body weight per day.
  • the compound is provided in a dosage of about lOmg/kg of body weight per day.
  • “About” as referred to herein refers to any specific value referred to in this specification, e.g., the indicated dosage, including any variation which is within the range of +/-20%, +/-10%, +/- 5%, +/-4%, +/-3%, +1-2% or +/-!%.
  • the compound for use according to the present invention preferably R- Flurbiprofen or Nitro-R-Flurbiprofen, upon administration shall lower the blood glucose level.
  • Methods to determine the blood glucose level are well known in the art and measurement devices for determining blood glucose levels are commercially available.
  • envisaged in accordance wit the present invention is a decrease in blood glucose level which is statistically significant and, more preferably, is a decrease of the blood glucose level by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60% or 70%.
  • pancreatic immune processes refers to immune system reactions against pancreatic tissue and, in particular, pancreatic islets, and include, for example, induction and propagation of autoimmunity, infiltration of immune cells, release of immunomodulatory cytokines and propagation of beta cell death.
  • Methods to diagnose pancreatic autoimmune processes are known to the skilled artisan and include, for example, determination of autoreactive antibodies or detection of inflammatory cytokines.
  • the compound for use according to the present invention and preferably (R)-Flurbiprofen or
  • Nitro-(R)-Flurbiprofen can be used alone or in combination with other compounds and treatments that are available for the prevention and/or treatment of diabetes.
  • Use in combination as referred to herein includes a simultaneous or sequential application of the compounds and treatments.
  • the compound according to the invention may be manufactures together with further diabetes drugs in a single composition as described elsewhere herein in more detail. Such applications may provide for synergistic effects achieved by the compounds administered in combination in the prevention and/or treatment of diabetes.
  • a further therapeutic agent for prevention and/or treatment of diabetes is, preferably, selected from the group consisting of: insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, statins, metformin, dexamethasone, thiazolidinediones, alpha- glucosidase inhibitors, synthetic analogs of human amylin, incretin mimetics, glitazones, sodium-glucose co -transporter 2 (SGLT2) inhibitors, anti-CD3 -antibodies, anti-CD20- antibodies, anti-CD20-antibodies, cyclosporines, azathioprine, antithymocyte globulin and nicotinamide.
  • GLP-1 glucagon-like peptide-1
  • DPP-4 dipeptidyl peptidase 4
  • statins metformin
  • dexamethasone thiazolidined
  • diabetes refers to disease conditions in which the glucose metabolism is impaired. Said impairment results in hyperglycaemia.
  • WHO World Health Organization
  • diabetes can be subdivided into four classes which are all individually encompassed by the term diabetes according to the present invention.
  • Type 1 diabetes is caused by a lack of insulin. Insulin is produced by pancreatic islet cells, the so called beta cells. Said cells may be destroyed by an autoimmune reaction in Type 1 diabetes (Type la). The progressive destruction of beta cells can last months or even years without clinical symptoms until a point is reached where the beta-cell mass is critically low, so that insulin concentrations are no longer adequate to control plasma glucose levels.
  • Type 1 diabetes is sometimes also referred to as "juvenile diabetes” because it mainly develops during childhood; however, it can also develop in adults. Type 1 diabetes is thought to be partly inherited and triggered by environmental factors, i.e. a viral infection, in genetically susceptible people. People with an increased risk of developing type I diabetes often have mutations in multiple genes.
  • Type 1 diabetes also encompasses an idiopathic variant (Type lb).
  • Idiopathic (Type lb) diabetes usually presents with the typical signs and symptoms of Type la diabetes such as diabetic ketoacidosis, but its subsequent clinical course often resembles Type 2 diabetes.
  • Type 2 diabetes is caused by an insulin resistance.
  • Type 2 diabetes is the most common form of diabetes and is primarily related to lifestyle factors such as obesity, poor diet and lack of physical activity.
  • genetic predispositions may also play an important role in the onset of type 2 diabetes, i.e.
  • Type 3 diabetes comprises all other specific types of diabetes characterized by an impaired glucose metabolism resulting in hyperglycaemia.
  • the beta cells may have genetic defects affecting insulin production, insulin resistance may be caused genetically or the pancreas as such may be destroyed or impaired.
  • hormone deregulation or drugs may also cause type 3 diabetes.
  • Type 4 diabetes which is also known as gestational diabetes, may occur during pregnancy. Gestational diabetes is thought to be linked to pregnancy-related factors such as the presence of human placental lactogen. These factors are likely to interfere with insulin receptor signalling, thus lowering the uptake of glucose into the cells causing elevated blood sugar levels. It will be understood by those skilled in the art, that diabetes as used herein also includes pre-diabetic states in which not all of the symptoms required to label a person as diabetic are present, but blood sugar is abnormally high. Prediabetic states may include, for example, impaired fasting glycaemia, impaired glucose tolerance, metabolic syndrome and obesity.
  • diabetes refers to diabetes Type 1.
  • Diagnostic methods include, for example, blood sugar tests (i.e. fasting blood sugar test or oral glucose tolerance test), determination of autoreactive antibodies (i.e. antibodies to insulin-producing beta-cells) and urine sample tests (i.e. ketone concentration in the urine).
  • Increased fasting blood sugar levels are indicative for diabetes in general, particularly a level larger than 125 mg/dL.
  • diabetes as used herein is characterized by a blood glucose level larger than 250mg/dL.
  • treating refers to ameliorating or curing a disease or at least one symptom associated therewith.
  • the treatment shall be deemed to be effective. It will be understood that treating might not be effective in all subjects. However, according to the present invention it is envisaged that treatment will be effective in at least a statistically significant portion of subjects to be treated. It is well known to the skilled artisan how to determine a statistically significant portion of subjects that can be effectively treated.
  • Whether a portion of subjects or any other value referred to herein is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools, e.g., determination of confidence intervals, p-value determination, Student ' s t-test, Mann- Whitney test etc.. Details are found in Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York 1983.
  • Preferred confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99%.
  • the p- values are, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001.
  • the probability envisaged by the present invention allows that the finding of effective treatment will be correct for at least 60%, at least 70%, at least 80%, or at least 90% of the subjects of a given cohort or population.
  • Therapeutic efficacy and toxicity of the compound according to the invention as a therapeutic agent can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population).
  • the dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.
  • the dosage regimen will be determined by the attending physician and by clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, age, the particular formulation of the medicament to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Progress can be monitored by periodic assessment. Dosage recommendations shall be indicated in the prescribers or users instructions in order to anticipate dose adjustments depending on the considered recipient.
  • preventing refers to avoiding the onset of a disease or at least one symptom thereof.
  • said disease is diabetes.
  • diabetes as used herein also includes pre-diabetic states in which not all of the symptoms required to label a person as diabetic are present, but blood sugar is abnormally high.
  • pre-diabetic states are also predisposing for the development of diabetes.
  • Pre-diabetic states in accordance with the present invention may include, for example, impaired fasting glycaemia, impaired glucose tolerance, metabolic syndrome and obesity.
  • hyperglycemia refers to a condition in which an excessive amount of glucose is circulating in the blood. Hyperglycemia is commonly also known as high blood sugar. According to the American Diabetes Association guidelines, a subject with a consistent range of about 5.6 mmol/1 and about 7.0 mmol/1 (100-126 mg/dl) is considered hyperglycemic. Above 7 mmol/1 (126 mg/dl), the subject is recognized as having diabetes.
  • metabolic syndrome refers to a disease in which at least three of five of the following medical conditions are present: abdominal (central) obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, and low high-density lipoprotein (HDL) levels.
  • Signs of metabolic syndrome include, for example impaired fasting glucose, insulin resistance high blood pressure, decreased fasting serum HDL cholesterol and elevated fasting serum triglyceride level (VLDL triglyceride).
  • the term "obesity" refers to a medical condition in which the body has acquired excess body fat to the extent that it may have a negative effect on health.
  • a subject is considered to have obesity when the body mass index (BMI) is higher than 30.
  • BMI body mass index
  • Methods to diagnose obesity including the calculation of the body mass index are known in the art.
  • the prevention as referred to herein can be typically achieved for the period during which a drug, preferably a compound or composition according to the present invention, is administered.
  • the prevention may not persist for an unlimited time but may remain present for a certain preventive time window after application of the drug.
  • the predictive time window for prevention of diabetes as used herein may be up to several weeks, months or even years.
  • the preventive time window in accordance with the present invention may be at least one week, two weeks, three weeks, four weeks, one month, two months, or three months. It will be understood that prevention might not be effective in all subjects. However, according to the present invention it is envisaged that prevention will be effective in at least a statistically significant portion of subjects. It is well known to the skilled artisan how to determine a statistically significant portion of subjects that can be effectively prevented. Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools as discussed above.
  • subject as used herein relates to animals, preferably to mammals such as mice, rats, sheep, dogs, cats, horses, monkeys, or cows and, also preferably, to humans.
  • a subject as used herein refers to a subject suspected to suffer from diabetes or to have an increased predisposition of developing diabetes and thus is in need for a therapy for preventing and/or treating diabetes.
  • the subject shows symptoms or clinical signs or parameters indicative for diabetes.
  • the subject when suffering from diabetes has a blood glucose level larger than 125 mg/dL. More preferably, the subject has a blood glucose level larger than 250mg/dL.
  • the term also relates to an apparently healthy subject, i.e. a subject not exhibiting any of the aforementioned symptoms, clinical signs or parameters.
  • the apparently healthy subject has an increased predisposition of developing diabetes and may be, therefore, in a pre-diabetic state as referred to elsewhere herein.
  • predisposition means that a subject has not yet developed the disease or any of the aforementioned disease symptoms or other diagnostic criteria but, nevertheless, will develop the disease in the future with a certain likelihood. Said likelihood shall differ significantly from the likelihood of statistical appearance of diabetes mellitus. Preferably, the likelihood for developing diabetes is at least 30%, at least 40%, at least 50%>, at least 60%>, at least 70%>, at least 80%>, at least 90%> or 100% of a predisposition is diagnosed. Diagnosis of a predisposition may sometimes be referred to as prognosis or prediction of the likelihood that a subject will develop the disease.
  • Risk factors that increase the likelihood of developing diabetes may include, for example certain genetic mutations, lifestyle parameters such as smoking or low physical activity, and obesity. More generally, the present invention also contemplates the use of a compound as defined above and, preferably, (R)-Flurbiprofen or Nitro-(R)-Flurbiprofen for the manufacture of a medicament for the prevention and/or treatment of diabetes.
  • Another general aspect of the present invention relates to a method for prevention and/or treatment of diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to the present invention, and, preferably, (R)- Flurbiprofen or Nitro-(R)-Flurbiprofen.
  • a compound according to the present invention and, preferably, (R)- Flurbiprofen or Nitro-(R)-Flurbiprofen, is suited for the prevention and/or treatment of diabetes.
  • (R)-Fluriprofen suppresses hyperglycemia, delays diabetic progression and affects the incidence of diabetes.
  • administration of (R)-Flurbiprofen was shown to affect different phases of diabetes type I pathology such as induction of autoimmunity, infiltration of immune cells and propagation of beta cell death.
  • (R)-flurbiprofen or a composition comprising (R)-Fluriprofen may be especially beneficial for patients with diabetes type I and may help to reduce necessary insulin amount and injections, limiting potential side effects associated therewith.
  • the compound according to the present invention shall also effect other types of diabetes being accompanied by increased blood glucose levels as well.
  • the compound shall have preventive potential as well as it shall be capable of preventing, ameliorating or reversing hyperglycemic states in general.
  • composition according to the present invention is (R)-Flurbiprofen (Tarenflurbil) or Nitro-(R)-Flurbiprofen.
  • said diabetes is characterized by a blood glucose level >250mg/dl.
  • said subject has an increased predisposition of developing diabetes.
  • said subject is suffering from hyperglycemia, metabolic syndrome and/or obesity.
  • said diabetes is diabetes mellitus type I, diabetes mellitus type II or gestational diabetes.
  • said compound decreases upon administration the blood glucose level.
  • said compound inhibits pancreatic autoimmune processes.
  • pancreatic immune processes refers to attacks of the body ' s immune system against pancreatic tissue and include, for example, induction and propagation of autoimmunity, infiltration of immune cells, release of immunomodulatory cytokines and propagation of beta cell death.
  • Methods to diagnose pancreatic autoimmune processes are known to the skilled artisan and include, for example, determination of autoreactive antibodies or detection of inflammatory cytokines.
  • said compound is provided in a dosage between 5 mg/kg of body weight to 15 mg/kg of body weight per day.
  • said compound is administered orally, topically, rectally or by injection. More preferably, the compound is administered orally.
  • said compound is provided in form of a tablet, capsule, dragee, powder, suppository, gel, cream, spray, ointment and/or solution.
  • said compound is provided in combination with at least one additional therapeutic agent for prevention and/or treatment of diabetes.
  • therapeutic agent refers to an agent that prevents, ameliorates or cures the symptoms accompanying a disease or condition referred to in this specification.
  • said at least one additional therapeutic agent is selected from the group consisting of: insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, statins, metformin, dexamethasone, thiazolidinediones, alpha- glucosidase inhibitors, synthetic analogs of human amylin, incretin mimetics, glitazones, sodium-glucose co -transporter 2 (SGLT2) inhibitors, anti-CD3 -antibodies, anti-CD20- antibodies, anti-CD20-antibodies, cyclosporines, azathioprine, antithymocyte globulin and nicotinamide.
  • GLP-1 glucagon-like peptide-1
  • DPP-4 dipeptidyl peptidase 4
  • statins metformin
  • dexamethasone thiazolidinediones
  • the present invention also provides a composition
  • a composition comprising (i) a compound according to the present invention, a nitro-variant of said compound, or pharmaceutically acceptable salts of said compound; and (ii) at least one additional therapeutic agent for prevention and/or treatment of diabetes.
  • composition refers to mixture of the aforementioned compounds according to the invention. Moreover, the composition may comprise further components as well such as further therapeutic or auxiliary ingredients and/or pharmaceutically acceptable carriers and/or diluents.
  • the composition of the present invention is, preferably, a pharmaceutical composition to be used as a medicament. Said medicament is, preferably, applied to treat and/or prevent diabetes as described elsewhere herein in detail.
  • such further ingredients of the composition of the invention can be stabilizing agents, wetting agents, pharmaceutical carriers, additional pharmaceutically active agents, release controlling agents and the like.
  • Preferred diluents encompass water, alcohols, physiological saline solutions, buffers, such as phosphate buffered saline solutions, syrup, oil, water, emulsions, various types of wetting agents, and the like.
  • a pharmaceutically acceptable diluent according to the invention is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solutions, dextrose solution, and Hank's solution.
  • the pharmaceutical composition or formulation may also include other carriers, adjuvants, or non-toxic, non-therapeutic, non-immunogenic stabilizers and the like.
  • a pharmaceutically acceptable carrier according to the invention must be acceptable in the sense of being compatible with the other ingredients of the formulation and being not deleterious to the recipient thereof.
  • the pharmaceutical carrier employed may include a solid, a gel, or a liquid.
  • Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
  • Said suitable carriers comprise those mentioned above and others well known in the art, see, e.g., Remington ' s Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania.
  • the composition shall be adapted for use in treating and/or preventing diabetes.
  • the desired mode of administration will be systemic administration.
  • the composition of the invention is, preferably, formulated for a systemic application.
  • oral application e.g. in the form of tablets, solution or drinking ampules, is envisaged or application via injection.
  • the composition may be administered by other routes as well including dermal, intra-muscular, subcutaneous, oral, intravenous or topical administration.
  • the composition can be, preferably, formulated for a bolus administration or can be made for continuous applications as set forth elsewhere herein in detail.
  • composition of the invention shall, preferably, comprise the therapeutically active compounds referred to above in a therapeutically effective dose.
  • Therapeutic efficacy and toxicity of the compound can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) as describe above already.
  • the composition of the present invention can be prepared in a manner well known in the pharmaceutical art.
  • the therapeutically active ingredients will usually be mixed and, preferably, combined with a carrier or the diluent.
  • the resulting formulations are to be adapted to the mode of administration.
  • the procedures for formulating a medicament as referred to herein may involve mixing, granulating, compression or dissolving the ingredients as appropriate to form the desired composition.
  • the form and character of the pharmaceutical acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration, and other well-known variables. Dosage recommendations shall be indicated in the prescribers or users instructions in order to anticipate dose adjustments depending on the considered recipient.
  • the formulation of a composition according to the invention as a medicament takes place under GMP standardized conditions or the like in order to ensure quality, pharmaceutical security, and effectiveness of the medicament.
  • said at least one additional therapeutic agent is selected from the group consisting of: insulin, glucagon-like peptide- 1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, statins, metformin, dexamethasone, thiazolidinediones, alpha-glucosidase inhibitors, synthetic analogs of human amylin, incretin mimetics, glitazones, sodium-glucose co -transporter 2 (SGLT2) inhibitors.
  • anti-CD3-antibodies, anti-CD20-antibodies, anti-CD20-antibodies, cyclosporines, azathioprine, antithymocyte globulin and nicotinamide is selected from the group consisting of: insulin, glucagon-like peptide- 1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, statins, metformin, de
  • Figure 1 Chemically induced diabetes by multiple low dose streptozotocin (5 times 40 mg/kg).
  • Figure IB Relative number of diabetic mice following start of streptozotocin application on day 0. Diabetes was defined as blood glucose > 250 mg/dl.
  • Figure ID Insulin staining in pancreatic islets using specific anti-insulin antibody.
  • Figure 2 Daily application of R-flurbiprofen (10 mg/kg), starting on day 0 together with streptozotocin application.
  • Figure 2 Daily application of R-flurbiprofen (10 mg/kg), starting on day 0 together with streptozotocin application.
  • Figure 2 Daily application of R-flurbiprofen (10 mg/kg
  • FIG. 2B Relative number of diabetic mice following administration of R-flurbiprofen. Diabetes was defined as blood glucose > 250 mg/dl.
  • Figure 2D Relative number of diabetic mice following administration of S-flurbiprofen. Diabetes was defined as blood glucose > 250 mg/dl.
  • Figure 3 Application of R-flurbiprofen for different time courses.
  • Figure 3C Suppression of streptozotocin induced hyperglycemia by short term application of R-flurbiprofen from day 14 to day 21.
  • FIG. 4 Summary of administration of R-flurbiprofen for different time courses.
  • Figure 5 Model: virus induced RIP-LCMV mouse model.
  • Figure 5B Relative number of LCMV induced diabetic mice following administration of R-flurbiprofen. Diabetes was defined as blood glucose > 300 mg/dl
  • Example 1 Induction of diabetes in mice by streptozotocin Male C57BL/6J specific pathogen- free mice, 10-20 weeks old, were bred in the animal facility. Mice were housed at 2-5 mice per cage at constant room temperature (21 +/- 1°C) under a regular light/dark schedule with light from 7:00 a.m. to 7:00 p.m. Food (standard chow) and water (sterile- filtered) were available ad libitum. Experimental autoimmune diabetes was induced by the multiple low dose streptozotocin method (MLD-STZ).
  • MLD-STZ multiple low dose streptozotocin method
  • Streptozotocin STZ was dissolved in 0.1 M citrate buffer (pH 4.5) and injected i.p., within 10 min of preparation, at a dose of 40 mg/kg/day for 5 consecutive days (d0-d4). Plasma glucose was monitored over the following 21 days on days 0, 9, 11, 14 and 21. The blood samples were obtained from the tail vein of non-fasted mice and glucose was measured using a glucometer. Mice were considered diabetic when their non-fasting blood glucose levels were > 250 mg/dl. On day 21 mice were euthanized by injection of ketamine/xylazine followed by cardiac puncture.
  • pancreas sections were stained for expression of insulin. Entire undamaged pancreata were embedded in optimal cutting temperature (OCT) compound, hardened on solid carbon dioxide and stored at -80 °C.
  • Cryosection of pancreatic tissue was performed on a microtome-cryostat. Sections of 7 ⁇ thickness were cut and mounted on sialin-coated Superfrost Plus slides, 6 ⁇ tissue sections were cut. Sections were then fixed with 90% ethanol at -20°C, and, after washing in PBS, an avidin/biotin-blocking step was included. Primary anti-insulin antibodies and biotinylated secondary antibodies were reacted with the sections for 60 min each, and color reaction was obtained by sequential incubation with avidin-peroxidase conjugate and diaminobenzidine-hydrogen peroxide.
  • STZ induced strong hyperglycemia in mice reaching significant diabetic levels around day 1 1 and highest blood glucose concentration at day 21 to day 40.
  • day 11 approximately 50% of the STZ-treated mice were diabetic, on day 14 75%>, on day 21 about 90%>, and on day 40 100%, respectively.
  • the increase in blood glucose concentration correlated well with the decrease in viable beta cells.
  • anti-insulin stained intra-islet area represents about 90% of total islet area.
  • STZ anti-insulin stained area was reduced to nearly 60%), and on day 21 a reduction in viable beta cells by about 70%> was observed.
  • R- flurbiprofen was administrated from day -2 to 21 to STZ-treated mice. On day 14 and 21 a significant decrease in blood glucose concentration compared to vehicle administrated STZ- treated mice was detected. Also some extent of hyperglycemia was observed only 25%> of R- flurbiprofen treated mice exhibited diabetes upon STZ application. In a striking contrast, vehicle-treated mice showed about 90%> of diabetes incidence on day 21 following STZ administration.
  • Example 4 Effects of R-flurbiprofen on blood glucose levels and diabetes incidence in the RIP-LCMV mouse model
  • the anti-diabetic action of R-flurbiprofen was studied in the virus induced RIP-LCMV mouse model.
  • the RIP-LCMV model uses the glycoprotein (GP) of LCMV as target antigens expressed by the ⁇ -cells. Diabetes is induced by infection with LCMV.
  • GP glycoprotein
  • 10 4 plaque forming units LCMV Armstrong clone 53 b were injected intraperitoneally.
  • R-flurbiprofen or vehicle were administrated from day -2 to 21.
  • R- flurbiprofen caused a significant decrease in diabetes induction in the early time course of the model with about 25% diabetic mice on day 10 compared to about 90% in vehicle treated mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé qui est un énantiomère R d'un composé de formule (I) suivante, dans laquelle R1 ou R2 représente un groupe choisi parmi H, -CH3, -CH2CH3, -CH2CH2CH3 et -CH2CH2CH2CH3 ou qui peut former conjointement avec un autre groupe un cycle cyclopropyle, un cycle cyclobutyle, un cycle cyclopentyle ou un cycle cyclohexyle, R3 représente un groupe choisi parmi -COOH, -COOR6, -CONH2, -CONHR6, -CONR6R7, -CONHSO2R6, -COO-(CH2)3-CH2OH, -COO-(CH2)4-ONO2, -COO-PhOCH3-C2H2-COO-(CH2)4-ONO2, un groupe tétrazolyle et un bioisostère du groupe -COOH, R4 ou R5 représente un groupe choisi parmi -Cl, -F, -Br, -I, -CF3, -OCF3, -SCF3, -OCH3, -OCH2CH3, -CN, -CH=CH2, -CH2OH et -NO2, R6 ou R7 représente un groupe choisi parmi -CH3, -CH2CH3, -CH2CH2CH3 et -CH2CH2CH2CH3, et m ou n est un nombre entier choisi parmi 0, 1, 2, et 3 ; une variante nitro dudit composé ou des sels de qualité pharmaceutique dudit composé, pour utilisation dans la prévention et/ou le traitement du diabète chez un sujet en ayant besoin. En outre, l'invention concerne également une composition comprenant ledit composé, sa variante nitro ou ses sels de qualité pharmaceutique et au moins un agent thérapeutique supplémentaire pour la prévention et/ou le traitement du diabète.
PCT/EP2016/076954 2015-11-09 2016-11-08 (r)-fluriprofène pour la prévention et/ou le traitement du diabète Ceased WO2017080989A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15193690.3 2015-11-09
EP15193690 2015-11-09

Publications (1)

Publication Number Publication Date
WO2017080989A1 true WO2017080989A1 (fr) 2017-05-18

Family

ID=54539887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/076954 Ceased WO2017080989A1 (fr) 2015-11-09 2016-11-08 (r)-fluriprofène pour la prévention et/ou le traitement du diabète

Country Status (1)

Country Link
WO (1) WO2017080989A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4019538A1 (fr) 2020-12-22 2022-06-29 Charité - Universitätsmedizin Berlin Reprogrammation de cellules immunitaires par une intégration ciblée de transgènes de récepteur d'antigène chimérique déficient en zêta

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008208091A (ja) * 2007-02-27 2008-09-11 Hiroshima Univ 小胞体ストレス関連疾患の治療薬および予防薬
US20090162421A1 (en) 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
WO2012059541A1 (fr) 2010-11-03 2012-05-10 Johann Wolfgang Goethe-Universität, Frankfurt Am Main Nouveau traitement de la sclérose en plaques (ms)
WO2013026772A1 (fr) 2011-08-19 2013-02-28 Johann Wolfgang Goethe-Universität Flurbiprofène et composés apparentés pour le traitement de troubles cutanés
WO2014159772A2 (fr) * 2013-03-14 2014-10-02 The Research Foundation For The Statw University Of New York Inhibition des effets toxiques de la formation d'amyloïdes d'îlots par du fluriprofène et des dérivés de fluriprofène

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008208091A (ja) * 2007-02-27 2008-09-11 Hiroshima Univ 小胞体ストレス関連疾患の治療薬および予防薬
US20090162421A1 (en) 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
WO2012059541A1 (fr) 2010-11-03 2012-05-10 Johann Wolfgang Goethe-Universität, Frankfurt Am Main Nouveau traitement de la sclérose en plaques (ms)
WO2013026772A1 (fr) 2011-08-19 2013-02-28 Johann Wolfgang Goethe-Universität Flurbiprofène et composés apparentés pour le traitement de troubles cutanés
WO2014159772A2 (fr) * 2013-03-14 2014-10-02 The Research Foundation For The Statw University Of New York Inhibition des effets toxiques de la formation d'amyloïdes d'îlots par du fluriprofène et des dérivés de fluriprofène

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY
COOKE ET AL.: "Type 1 diabetes mellitus in pediatrics", PEDIATR REV, vol. 29, no. 11, 2008, pages 374 - 84
DOWDY; WEARDEN: "Statistics for Research", 1983, JOHN WILEY & SONS
GEERTS: "Drug evaluation: (R)-flurbiprofen-an enantiomer of flurbiprofen for the treatment of Alzheimer's disease", DRUGS, vol. 10, no. 2, February 2007 (2007-02-01), pages 121 - 33
GREEN ET AL.: "Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial", JAMA, vol. 302, 2009, pages 2557 - 64
T.L. VAN BELLE ET AL: "Mouse models for Type 1 Diabetes", DRUG DISCOVERY TODAY: DISEASE MODELS, vol. 6, no. 2, 1 June 2009 (2009-06-01), pages 41 - 45, XP055045317, ISSN: 1740-6757, DOI: 10.1016/j.ddmod.2009.03.008 *
TAHEREH TABATABAIE ET AL: "COX-2 Inhibition Prevents Insulin-Dependent Diabetes in Low-Dose Streptozotocin-Treated Mice", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 273, no. 2, 1 July 2000 (2000-07-01), US, pages 699 - 704, XP055263889, ISSN: 0006-291X, DOI: 10.1006/bbrc.2000.2959 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4019538A1 (fr) 2020-12-22 2022-06-29 Charité - Universitätsmedizin Berlin Reprogrammation de cellules immunitaires par une intégration ciblée de transgènes de récepteur d'antigène chimérique déficient en zêta

Similar Documents

Publication Publication Date Title
US12343382B2 (en) Methods of using a GIP/GLP1 co-agonist for therapy
JP4846063B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
KR102412997B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
EA028049B1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
CN118453559A (zh) 炎症性疾病或骨病的预防或治疗剂及医药组合物
JP2019089825A (ja) 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
CN117677395A (zh) 长效glp1/胰高血糖素受体激动剂的剂量方案
KR20080021139A (ko) 편두통을 위한 드로나비놀 치료
US20100075937A1 (en) Patient populations and treatment methods
Gan et al. Safety evaluation of fospropofol for sedation during minor surgical procedures
US20220175793A1 (en) The use of an mglur5 antagonist for treating opioid analgesic tolerance
WO2017080989A1 (fr) (r)-fluriprofène pour la prévention et/ou le traitement du diabète
KR20240073926A (ko) 간 용적을 감소시키기 위한 레스메티롬
KR20200062240A (ko) 시포니모드의 투여 요법
EA021788B1 (ru) Сульфонамиды для профилактики диабета
JP2019038858A (ja) ペマフィブラートを含有する医薬
Mamo et al. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders
WO2007007668A1 (fr) Agent thérapeutique et procédé de traitement servant à améliorer l'urémie
WO2022051304A1 (fr) Formulations de liquides ioniques de traitement du diabète
US20200360331A1 (en) COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES
US20250367218A1 (en) Methods of treating metabolic disorders and combination products for use in the same
US20120283332A1 (en) Transdermal delivery of metformin
Zhong et al. Side effects of positive inotropic drugs and drugs used in dysrhythmias
CN114831998B (zh) 栓菌酸在肾病治疗中的应用
US20250302804A1 (en) Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16794297

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16794297

Country of ref document: EP

Kind code of ref document: A1